Up to now, the application of molecular biomarkers in the detection of CRC is limited to carcinoembryonic antigen (CEA) as a serum biomarker for monitoring disease recurrence or response to treatment and KRAS to detect resistance to the anti-EFGR chemotherapy drug Cetuximab26. Here, CEACAM5 is linked to colorectal carcinoma.